Clinical Trial

Breast Cancer WEight Loss Study (BWEL Study)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.
Protocol Amendment History 46 amendments
This ClinicalTrials.gov record has been amended 46 times since 2016-04-21; most recent amendment 2025-01-09.
Status change: Recruiting → Active, Not Recruiting 2021-03-05
Status change: Not Yet Recruiting → Recruiting 2016-08-29
Trial Details
NCT Number NCT02750826
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Division of Cancer Control, NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Canadian Cancer Trials Group
Conditions Breast Carcinoma
Enrollment 3,177 participants
Start Date 2016-09-16
Primary Completion 2030-05-30 (estimated)
Study Completion 2030-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-13